Friday, September 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica

View original at globenewswire.com
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Funding for AI-integrated cath lab solutions rose by 20% in 2024

    80% confidence
  • TriClip patients were 28% less likely to be hospitalized for heart failure and 90% of TriClip patients saw regurgitation reduction

    80% confidence
  • A 2025 analysis identified 51 major cardiovascular clinical trials published between 2019 and 2024, enrolling a total of 292,985 patients

    80% confidence
  • New clinical trial initiations surged by 68% in the decade ending 2024

    80% confidence
  • 46% of US counties operate without a single practicing cardiologist, while 86% of rural counties lack access entirely

    80% confidence
  • UK cardiac waiting list swelling to 421,433 patients by May 2024 and Canadian wait times reaching 194 days

    80% confidence
  • Vascular device investment reaching USD 759 million and cardiovascular venture investment stabilizing at USD 542 million in 2024

    80% confidence
  • FDA listed 1,176 devices in its Breakthrough Device Program as of August 2024, with 243 designations specifically allocated to cardiovascular innovations

    80% confidence
  • Medtronic's PulseSelect demonstrated an average skin-to-skin procedure time of just 36 minutes in 2024 with 98% of pulmonary veins remained isolated

    80% confidence
  • 45% of global cath lab equipment exports originating from US manufacturers in 2024

    80% confidence
  • Global shipments of wearable health devices reached 440 million units in 2024, with 160 million units specifically designated as medical sensors for clinical monitoring

    80% confidence
  • US market for smart wearable ECG monitors was valued at USD 586.91 million in 2024

    80% confidence
  • Medical tourism options for TAVR in India were priced at approximately USD 14,500 in 2024

    80% confidence
  • Total US cardiovascular deaths hit 931,578 with age-adjusted death rate rose to 233.3 per 100,000

    80% confidence
  • 127.9 million US adults had some form of cardiovascular disease in 2024

    80% confidence
  • Weekly procedure rates averaging 16,200 cases throughout 2024 for pulsed field ablation

    80% confidence
  • Boston Scientific's Farapulse procedures finished in under 90 minutes in 90% of cases, while thermal ablation only achieved this speed in 60% of cases

    80% confidence
  • The global cardiovascular devices market size was valued at USD 74.58 billion in 2025 and is projected to hit the market valuation of USD 157.32 billion by 2035 at a CAGR of 7.70% during the forecast period 2026–2035

    80% confidence
  • As of December 2025, over 2,000 cardiovascular drugs and device-delivery therapies were in active development

    80% confidence
  • Varipulse achieved an 80% recurrence-free rate

    80% confidence
  • FDA cleared a record 39 new clinical AI algorithms in May 2025, bringing the total to 116 cleared cardiology algorithms

    80% confidence
  • North America secured the largest geographical portion, contributing 45.68% of the revenue share in 2025

    80% confidence
  • Average cost for a TAVR procedure in 2024 ranged from USD 52,176 in Chicago to USD 81,889 in California

    80% confidence
  • Nearly 12.1 million people in the US are projected to be diagnosed with Atrial Fibrillation by 2030

    80% confidence
  • Projected global healthcare cost savings from wearable adoption estimated at USD 200 billion over the next 25 years

    80% confidence
  • MANIFEST-17K study reported a 0% rate of esophageal damage and pericardial tamponade rate of just 0.36%

    80% confidence
  • China accounted for 22.26% of the global cardiovascular disease burden

    80% confidence
  • The therapeutics & surgical devices category held a commanding position, accounting for a 77.5% revenue share in 2025

    80% confidence
  • Total surgical procedure volumes reached 18.9 million in 2024, with the United States and China accounting for 3.6 million and 3.5 million interventions, respectively

    80% confidence
  • Stroke caused 162,890 deaths in the US

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · cardiology ai algorithms total116 algorithms
U.S. Food and Drug Administration · ai algorithms cleared may 202539 algorithms
U.S. Food and Drug Administration · cleared breakthrough cvd devices 12mo16 devices
U.S. Food and Drug Administration · breakthrough cardiovascular devices243 devices
U.S. Food and Drug Administration · breakthrough devices total1176 devices
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica — Source | Via News | Via News